Tarsus Pharmaceuticals (TARS) Set to Release Quarterly Earnings on Tuesday

Tarsus Pharmaceuticals (NASDAQ:TARS) will likely be announcing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($1.49) per share and revenue of $186.56 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The company had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. On average, analysts expect Tarsus Pharmaceuticals to post ($4.19) EPS for the current fiscal year and $0.64 EPS for the next fiscal year.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $70.03 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. The company has a market cap of $3.45 billion, a P/E ratio of -64.25 and a beta of 0.44. The firm has a 50-day moving average of $75.06 and a 200-day moving average of $67.98. Tarsus Pharmaceuticals has a one year low of $53.89 and a one year high of $91.53.

Analysts Set New Price Targets

A number of brokerages have weighed in on TARS. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Jefferies Financial Group lifted their target price on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Guggenheim dropped their price objective on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Tuesday, July 21st. The Goldman Sachs Group initiated coverage on Tarsus Pharmaceuticals in a research note on Thursday, September 24th. They issued a “buy” rating and a $116.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $100.86.

Insider Transactions at Tarsus Pharmaceuticals

In related news, CEO Bobak Azamian sold 10,000 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $90.56, for a total transaction of $905,600.00. Following the completion of the sale, the chief executive officer directly owned 827,991 shares in the company, valued at $74,982,864.96. This represents a 1.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William Link, PhD sold 12,500 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $78.38, for a total value of $979,750.00. Following the completion of the sale, the director directly owned 94,487 shares of the company’s stock, valued at $7,405,891.06. The trade was a 11.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 48,031 shares of company stock valued at $4,004,227. Company insiders own 9.64% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.